# RNN 1st Gen Model McKesson Corporation Drugs, proprietaries, & sundries

Stock predictor AI models:
77.36% successful of 53 deals
$ 200.80 Last close price
at 18-oct-2021


Model's trade recommendations 0.94% Return for period

0.64% Annual return

$31.91B Market Cap

β 1.31  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 0.94%
52wk return 10.09%
52wk Range
Sortino ratio 0.12
Sharpe ratio 0.10
Norm. RMSE 1.07%
Downside risk 12.38%
Volatility 0.00%
  • 1.36 (0.88%) Div (Yield)
  • BUY Analysts consensus recommendation

McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by their ICARE shared principles, their employees work every day to innovate and deliver opportunities that make their customers and partners more successful - all for the better health of patients.

Industry sector: Medical

Sector classification: Drugs, proprietaries, & sundries

Deep Learning based analysis and prediction model for McKesson Corporation (MCK) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for MCK model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for MCK.

Model is being retrained on a daily basis.

Float 204M
P/E 12.33
Shares Outstanding 206M
% Held by Insiders 1.20%
% Held by Institutions 88.62%
EPS (last reported FY) $11.61
EPS (last reported Q) $3.41
EPS, estimated (last reported Q) $2.92
Total revenues $199 B
Net income $5 B